• Country / Location Selection

United States (US)

Epithelial–mesenchymal transition (EMT) Pathway


Epithelial–mesenchymal transition (EMT) is a process whereby tightly-interacting and immotile epithelial cells acquire the phenotype of loosely-adherent and motile mesenchymal cells. EMT not only facilitates morphogenesis during embryonic development but also promotes invasion and metastasis in tumors. Pathological EMT is associated with E-cadherin repression, which has been shown to contribute to tumor progression. Several oncogenic pathways (TGF-β, Wnt/β-catenin, Integrins, Notch, etc) have been reported to induce EMT via cytoskeleton reorganization and activation of E-Cadherin repressors, including Snail, Slug, SIP1, and TCF3. GeneTex is proud to introduce our new line of antibodies for the study of EMT.



Epithelial Cell Markers

E-Cadherin antibody [GT477]

beta Catenin antibody [N1N2-2], N-term (GTX101435)

Cytokeratin 8 antibody [N1C1]

Occludin antibody (GTX114949)

Mesenchymal Cell Markers

Vimentin antibody [GT812]

alpha Smooth Muscle Actin antibody (GTX100034)

N-Cadherin antibody (GTX127345)

Fibronectin antibody [N1N2], N-term (GTX112794)